VERLINGUE
12.12.2022 09:01:41 CET | Business Wire | Press release
The Adelaïde Group subsidiary and corporate protection specialist Verlingue is overhauling its visual identity and embracing a brand service promise to buoy its European ambitions.
Verlingue achieved a turnover of €211.6 million in 2021, up 11.9%, of which 27% outside France, and announced the acquisition of a new broker in Portugal, RT Global Insurance.
A new identity rolled out simultaneously in France, Great Britain, Switzerland and Portugal to uphold its ambitions of becoming a leading independent insurance broker on a European scale
Spurred on by plans to deepen its European foothold, Verlingue is making changes to its brand platform to accentuate its uniqueness and uphold its new tagline: “Protecting today. Imagining tomorrow”.
The broker hopes to shine a light on both its model’s stability and ambitions. In a world where new and emerging risks are multiplying, Verlingue embraces forward-looking risk management, helping clients manage any potential constraints on their activities, drive growth and improve overall performance.
Verlingue continues expanding across Europe with a new acquisition in Portugal
Two years to the day after acquiring Luso Atlantica, Verlingue acquires RT Global Insurance, a company specialized in P&C, which is set to generate growth of 15% for Verlingue Portugal.
“We want to remain an independent and family-owned company, a trusted partner while expanding across France and abroad, being ambitious while offering an alternative compared to more global or finance-led names. Today we are taking a step forward in our objective to build an attractive project for the teams who decide to join our adventure and to build a large European insurance broker,” notes Jacques Verlingue, Chairman of the Adelaïde Group.
Drawing on identity, values and unique expertise in becoming one of Europe’s leading independent insurance brokers
At the dawn of its 90th anniversary, Verlingue is continuing to take a long-term approach in becoming a major European, family-owned and independent insurance broker.
Ever faithful to the Impact 24 strategic plan, the Adelaïde Group is confirming its ambitions to hit sales of €400M to €500M through profitable organic growth and strategic European acquisitions focused on industrial interest.
About Verlingue
An insurance broker specializing in corporate protection, Verlingue is a subsidiary of the Adelaïde Group working alongside entrepreneurs.
With offices in France, Great Britain, Switzerland and Portugal, and through partners in over 100 countries, Verlingue works with its clients over the long term and at all times to better understand and anticipate new and emerging risks in order to develop simple and effective solutions to protect their business (corporate risk) and staff (employee benefits and pensions).
1,200 employees, 400 of whom are based outside France
€2.2B in premiums negotiated on behalf of its clients
24 offices in Europe
LinkedIn / www.verlingue.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release
IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release
BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom